These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 36414195)

  • 1. Optimization of storage conditions for lipid nanoparticle-formulated self-replicating RNA vaccines.
    Kim B; Hosn RR; Remba T; Yun D; Li N; Abraham W; Melo MB; Cortes M; Li B; Zhang Y; Dong Y; Irvine DJ
    J Control Release; 2023 Jan; 353():241-253. PubMed ID: 36414195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Optimization of a Freeze-Drying Process Achieving Enhanced Long-Term Stability and In Vivo Performance of Lyophilized mRNA-LNPs.
    Alejo T; Toro-Córdova A; Fernández L; Rivero A; Stoian AM; Pérez L; Navarro V; Martínez-Oliván J; de Miguel D
    Int J Mol Sci; 2024 Oct; 25(19):. PubMed ID: 39408932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.
    Schoenmaker L; Witzigmann D; Kulkarni JA; Verbeke R; Kersten G; Jiskoot W; Crommelin DJA
    Int J Pharm; 2021 May; 601():120586. PubMed ID: 33839230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine.
    Muramatsu H; Lam K; Bajusz C; Laczkó D; Karikó K; Schreiner P; Martin A; Lutwyche P; Heyes J; Pardi N
    Mol Ther; 2022 May; 30(5):1941-1951. PubMed ID: 35131437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions.
    Reinhart AG; Osterwald A; Ringler P; Leiser Y; Lauer ME; Martin RE; Ullmer C; Schumacher F; Korn C; Keller M
    Mol Pharm; 2023 Dec; 20(12):6492-6503. PubMed ID: 37975733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous freeze-drying of messenger RNA lipid nanoparticles enables storage at higher temperatures.
    Meulewaeter S; Nuytten G; Cheng MHY; De Smedt SC; Cullis PR; De Beer T; Lentacker I; Verbeke R
    J Control Release; 2023 May; 357():149-160. PubMed ID: 36958400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemistry of Lipid Nanoparticles for RNA Delivery.
    Eygeris Y; Gupta M; Kim J; Sahay G
    Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids.
    Lamoot A; Lammens J; De Lombaerde E; Zhong Z; Gontsarik M; Chen Y; De Beer TRM; De Geest BG
    Biomater Sci; 2023 Jun; 11(12):4327-4334. PubMed ID: 37073472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and lyophilization of mRNA-encapsulating lipid nanoparticles.
    Wang T; Yu T; Li W; Liu Q; Sung TC; Higuchi A
    Int J Pharm; 2024 Sep; 662():124514. PubMed ID: 39067550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA.
    Barbieri BD; Peeler DJ; Samnuan K; Day S; Hu K; Sallah HJ; Tregoning JS; McKay PF; Shattock RJ
    J Control Release; 2024 Oct; 374():280-292. PubMed ID: 39142355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization.
    Ball RL; Bajaj P; Whitehead KA
    Int J Nanomedicine; 2017; 12():305-315. PubMed ID: 28115848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses.
    Wan J; Wang Z; Wang L; Wu L; Zhang C; Zhou M; Fu ZF; Zhao L
    mBio; 2024 Jan; 15(1):e0177523. PubMed ID: 38078742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
    Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
    Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical and structural insights into lyophilized mRNA-LNP from lyoprotectant and buffer screenings.
    Fan Y; Rigas D; Kim LJ; Chang FP; Zang N; McKee K; Kemball CC; Yu Z; Winkler P; Su WC; Jessen P; Hura GL; Chen T; Koenig SG; Nagapudi K; Leung D; Yen CW
    J Control Release; 2024 Sep; 373():727-737. PubMed ID: 39059500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications.
    Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of an Alcohol Dilution-Lyophilization Method for the Preparation of mRNA-LNPs with Improved Storage Stability.
    Shirane D; Tanaka H; Sakurai Y; Taneichi S; Nakai Y; Tange K; Ishii I; Akita H
    Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery.
    Maeki M; Uno S; Niwa A; Okada Y; Tokeshi M
    J Control Release; 2022 Apr; 344():80-96. PubMed ID: 35183654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
    Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
    Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bivalent mRNA vaccines against three SARS-CoV-2 variants mediated by new ionizable lipid nanoparticles.
    Wang J; Zhang Y; Dong S; Zha W; Liu C; Wang Y; Jiang Y; Xing H; Li X
    Int J Pharm; 2023 Jul; 642():123155. PubMed ID: 37402442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines.
    Shepherd SJ; Han X; Mukalel AJ; El-Mayta R; Thatte AS; Wu J; Padilla MS; Alameh MG; Srikumar N; Lee D; Weissman D; Issadore D; Mitchell MJ
    Proc Natl Acad Sci U S A; 2023 Aug; 120(33):e2303567120. PubMed ID: 37556502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.